|Description||CH5137291 is a potent androgen receptor (AR) pure antagonist which did not produce the agonist metabolite with AR nuclear translocation-inhibiting activity. It inhibits the growth of castration-resistant prostate cancer cells. It offers a novel therapeutic approach against major types of castration-resistant prostate cancers.|
|Solubility||10 mM in DMSO|
|Application||CH5137291 offers a novel therapeutic approach against major types of castration-resistant prostate cancers.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||654.4±65.0 °C | Condition: Press: 760 Torr|
|Density||1.65±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
N-desmethyl Enzalutamide is a major metabolite of Enzalutamide. Enzalutamide is an androgen-receptor (AR) antagonist (IC50 = 36 nM) in LNCaP cells that inhibits...
Enzalutamide is an androgen-receptor (AR) antagonist with IC50 of 36 nM. It inhibits the activity of prostate cancer cell Ars, which over expressed in prostate ...
CH5137291 is a potent androgen receptor (AR) pure antagonist which did not produce the agonist metabolite with AR nuclear translocation-inhibiting activity. It ...
MK-0773 is a selective androgen receptor modulator for the prevention and treatment of muscle wasting associated with cancer. It designed to improve muscle func...
BMS-564929 is a novel androgen receptor (AR) modulator (Ki= 2.11 nM) which has been advanced to clinical trials for the treatment of age-related functional decl...
Cyproterone acetate is a synthetic derivative of 17-hydroxyprogesterone, and acts as an androgen receptor antagonist as well as a weak progesterone receptor ago...
RAD140, an effective non-steroidal selective androgen receptor modulator, could probably stimulate the increasing of muscle and also has been found to have pote...
Fasobegron acts a β3-adrenoreceptor agonist.
GLPG0492 R enantiomer
The R-enantiomer of GLPG0492 which is a selective androgen receptor modulator, could be effective in decreasing muscle loss.
RU 58841 is a new non-steroidal antiandrogen which has potential for use in treating androgen-dependent skin disorders such as acne, hirsutism and androgen-depe...
Pyrvinium pamoate, a nonabsorbed anthelmintic drug, is a potent androgen receptor inhibitor and a selective WNT pathway inhibitor. Pyrvinium pamoate is a potent...
AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patie...
ASC-J9 is an AR degradation enhancer, suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen rece...
Spironolactone is a potent antagonist of the androgen receptor with IC50 of 77 nM.
LGD-2226 is a selective androgen receptor modulator used in the treatment of muscle wasting and osteoporosis, shows to have an anabolic effect on muscle and bon...
JNJ-26146900 is a selective, nonsteroidal androgen receptor modulator with tissue-selective activity in rats. It can bind to the rat AR with a Ki of 400nM and a...
MK-3984 is a androgen receptor modulators. It can be used for the prevention and treatment of muscle wasting associated with cancer.
Bicalutamide is a non-steroidal androgen receptor (AR) antagonist with IC50 of 0.16 μM.
Flutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor with Ki values of 55 nM, and primarily used to treat prostate cancer...
Cortexolone 17 alpha-propionate
Cortexolone 17 alpha-propionate, also called as CB-03-01, belonging to the family of ester derivatives of cortexolone, is a potent and topical and peripherally ...